{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,26]],"date-time":"2025-07-26T08:52:39Z","timestamp":1753519959877,"version":"3.32.0"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,1,10]],"date-time":"2025-01-10T00:00:00Z","timestamp":1736467200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,1,10]],"date-time":"2025-01-10T00:00:00Z","timestamp":1736467200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100004699","name":"Chung Shan Medical University Hospital","doi-asserted-by":"publisher","award":["CSH-2021-C-031"],"award-info":[{"award-number":["CSH-2021-C-031"]}],"id":[{"id":"10.13039\/501100004699","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Taiwan National Science and Technology Council","award":["MOST 111-2314-B-040-131","MOST 111-2320-B-040-018-MY3"],"award-info":[{"award-number":["MOST 111-2314-B-040-131","MOST 111-2320-B-040-018-MY3"]}]},{"DOI":"10.13039\/501100007632","name":"Changhua Christian Hospital","doi-asserted-by":"publisher","award":["097-CCH-CSMU-04"],"award-info":[{"award-number":["097-CCH-CSMU-04"]}],"id":[{"id":"10.13039\/501100007632","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Chemother Pharmacol"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1007\/s00280-024-04734-9","type":"journal-article","created":{"date-parts":[[2025,1,10]],"date-time":"2025-01-10T08:16:02Z","timestamp":1736496962000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Endoglin as a predictive biomarker for pemetrexed sensitivity in non-small-cell lung cancer: a cellular study"],"prefix":"10.1007","volume":"95","author":[{"given":"Ching-Yuan","family":"Cheng","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wen-Chen","family":"Chuang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ching-Pin","family":"Lin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Che-Hsing","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hui-Yi","family":"Chang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wen-Jun","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ming-Fang","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiunn-Liang","family":"Ko","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,1,10]]},"reference":[{"issue":"4","key":"4734_CR1","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1051\/bmdcn\/2017070423","volume":"7","author":"CY Huang","year":"2017","unstructured":"Huang CY, Ju DT, Chang CF, Muralidhar Reddy P, Velmurugan BK (2017) A review on the effects of current chemotherapy drugs and natural agents in treating non-small cell lung cancer. Biomed (Taipei) 7(4):23. https:\/\/doi.org\/10.1051\/bmdcn\/2017070423","journal-title":"Biomed (Taipei)"},{"issue":"4","key":"4734_CR2","doi-asserted-by":"publisher","first-page":"249","DOI":"10.6004\/jnccn.2204.0023","volume":"22","author":"GJ Riely","year":"2024","unstructured":"Riely GJ, Wood DE, Ettinger DS, Aisner DL, Akerley W, Bauman JR, Bharat A, Bruno DS, Chang JY, Chirieac LR, DeCamp M, Desai AP, Dilling TJ, Dowell J, Durm GA, Gettinger S, Grotz TE, Gubens MA, Juloori A, Lackner RP, Lanuti M, Lin J, Loo BW, Lovly CM, Maldonado F, Massarelli E, Morgensztern D, Mullikin TC, Ng T, Owen D, Owen DH, Patel SP, Patil T, Polanco PM, Riess J, Shapiro TA, Singh AP, Stevenson J, Tam A, Tanvetyanon T, Yanagawa J, Yang SC, Yau E, Gregory KM, Hang L (2024) Non-small Cell Lung Cancer, Version 4.2024, NCCN Clinical Practice guidelines in Oncology. J Natl Compr Canc Netw 22(4):249\u2013274. https:\/\/doi.org\/10.6004\/jnccn.2204.0023","journal-title":"J Natl Compr Canc Netw"},{"issue":"2","key":"4734_CR3","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1158\/1535-7163.Mct-06-0343","volume":"6","author":"S Chattopadhyay","year":"2007","unstructured":"Chattopadhyay S, Moran RG, Goldman ID (2007) Pemetrexed: biochemical and cellular pharmacology, mechanisms, and clinical applications. Mol Cancer Ther 6(2):404\u2013417. https:\/\/doi.org\/10.1158\/1535-7163.Mct-06-0343","journal-title":"Mol Cancer Ther"},{"issue":"24","key":"4734_CR4","doi-asserted-by":"publisher","first-page":"16807","DOI":"10.18632\/oncotarget.24704","volume":"9","author":"R Tanino","year":"2018","unstructured":"Tanino R, Tsubata Y, Harashima N, Harada M, Isobe T (2018) Novel drug-resistance mechanisms of pemetrexed-treated non-small cell lung cancer. Oncotarget 9(24):16807\u201316821. https:\/\/doi.org\/10.18632\/oncotarget.24704","journal-title":"Oncotarget"},{"issue":"8","key":"4734_CR5","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.1097\/JTO.0b013e3181e0b954","volume":"5","author":"MF Wu","year":"2010","unstructured":"Wu MF, Hsiao YM, Huang CF, Huang YH, Yang WJ, Chan HW, Chang JT, Ko JL (2010) Genetic determinants of pemetrexed responsiveness and nonresponsiveness in non-small cell lung cancer cells. J Thorac Oncol 5(8):1143\u20131151. https:\/\/doi.org\/10.1097\/JTO.0b013e3181e0b954","journal-title":"J Thorac Oncol"},{"issue":"2","key":"4734_CR6","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1038\/onc.2016.195","volume":"36","author":"LY Chiu","year":"2017","unstructured":"Chiu LY, Hsin IL, Yang TY, Sung WW, Chi JY, Chang JT, Ko JL, Sheu GT (2017) The ERK-ZEB1 pathway mediates epithelial-mesenchymal transition in pemetrexed resistant lung cancer cells with suppression by vinca alkaloids. Oncogene 36(2):242\u2013253. https:\/\/doi.org\/10.1038\/onc.2016.195","journal-title":"Oncogene"},{"issue":"2","key":"4734_CR7","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1016\/s0021-9150(00)00422-6","volume":"153","author":"BA Conley","year":"2000","unstructured":"Conley BA, Smith JD, Guerrero-Esteo M, Bernabeu C, Vary CP (2000) Endoglin, a TGF-beta receptor-associated protein, is expressed by smooth muscle cells in human atherosclerotic plaques. Atherosclerosis 153(2):323\u2013335. https:\/\/doi.org\/10.1016\/s0021-9150(00)00422-6","journal-title":"Atherosclerosis"},{"issue":"27","key":"4734_CR8","doi-asserted-by":"publisher","first-page":"4450","DOI":"10.1038\/sj.onc.1208644","volume":"24","author":"E P\u00e9rez-G\u00f3mez","year":"2005","unstructured":"P\u00e9rez-G\u00f3mez E, Eleno N, L\u00f3pez-Novoa JM, Ramirez JR, Velasco B, Letarte M, Bernab\u00e9u C, Quintanilla M (2005) Characterization of murine S-endoglin isoform and its effects on tumor development. Oncogene 24(27):4450\u20134461. https:\/\/doi.org\/10.1038\/sj.onc.1208644","journal-title":"Oncogene"},{"key":"4734_CR9","doi-asserted-by":"publisher","unstructured":"Schoonderwoerd MJA, Goumans MTH, Hawinkels L (2020) Endoglin: beyond the endothelium. Biomolecules 10(2). https:\/\/doi.org\/10.3390\/biom10020289","DOI":"10.3390\/biom10020289"},{"issue":"6","key":"4734_CR10","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1242\/jcs.023283","volume":"121","author":"S Velasco","year":"2008","unstructured":"Velasco S, Alvarez-Mu\u00f1oz P, Pericacho M, Dijke Pt, Bernab\u00e9u C, L\u00f3pez-Novoa JM, Rodr\u00edguez-Barbero A (2008) L-and S-endoglin differentially modulate TGF\u03b21 signaling mediated by ALK1 and ALK5 in L6E9 myoblasts. J Cell Sci 121(6):913\u2013919","journal-title":"J Cell Sci"},{"key":"4734_CR11","doi-asserted-by":"publisher","unstructured":"Galaris G, Montagne K, Thalgott JH, Goujon G, van den Driesche S, Martin S, Mager HJ, Mummery CL, Rabelink TJ, Lebrin F (2021) Thresholds of Endoglin expression in endothelial cells explains vascular etiology in Hereditary Hemorrhagic Telangiectasia Type 1. Int J Mol Sci 22(16). https:\/\/doi.org\/10.3390\/ijms22168948","DOI":"10.3390\/ijms22168948"},{"issue":"6","key":"4734_CR12","first-page":"2283","volume":"31","author":"F Nassiri","year":"2011","unstructured":"Nassiri F, Cusimano MD, Scheithauer BW, Rotondo F, Fazio A, Yousef GM, Syro LV, Kovacs K, Lloyd RV (2011) Endoglin (CD105): a review of its role in angiogenesis and tumor diagnosis, progression and therapy. Anticancer Res 31(6):2283\u20132290","journal-title":"Anticancer Res"},{"issue":"2","key":"4734_CR13","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1007\/s10456-019-09703-y","volume":"23","author":"C Ollauri-Ib\u00e1\u00f1ez","year":"2020","unstructured":"Ollauri-Ib\u00e1\u00f1ez C, N\u00fa\u00f1ez-G\u00f3mez E, Egido-Turri\u00f3n C, Silva-Sousa L, D\u00edaz-Rodr\u00edguez E, Rodr\u00edguez-Barbero A, L\u00f3pez-Novoa JM, Pericacho M (2020) Continuous endoglin (CD105) overexpression disrupts angiogenesis and facilitates tumor cell metastasis. Angiogenesis 23(2):231\u2013247. https:\/\/doi.org\/10.1007\/s10456-019-09703-y","journal-title":"Angiogenesis"},{"issue":"1","key":"4734_CR14","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1002\/mc.23355","volume":"61","author":"E Laukhtina","year":"2022","unstructured":"Laukhtina E, Schuettfort VM, D\u2019Andrea D, Pradere B, Mori K, Quhal F, Sari Motlagh R, Mostafaei H, Katayama S, Grossmann Ncapital Es C, Rajwa P, Zeinler F, Abufaraj M, Moschini M, Zimmermann K, Karakiewicz PI, Fajkovic H, Scherr D, Comperat E, Nyirady P, Rink M, Enikeev D, Shariat SF (2022) Preoperative plasma level of endoglin as a predictor for disease outcomes after radical cystectomy for nonmetastatic urothelial carcinoma of the bladder. Mol Carcinog 61(1):5\u201318. https:\/\/doi.org\/10.1002\/mc.23355","journal-title":"Mol Carcinog"},{"issue":"1","key":"4734_CR15","doi-asserted-by":"publisher","first-page":"vdac041","DOI":"10.1093\/noajnl\/vdac041","volume":"4","author":"E Galanis","year":"2022","unstructured":"Galanis E, Anderson SK, Twohy E, Butowski NA, Hormigo A, Schiff D, Omuro A, Jaeckle KA, Kumar S, Kaufmann TJ, Geyer S, Kumthekar PU, Campian J, Giannini C, Buckner JC, Wen PY (2022) Phase I\/randomized phase II trial of TRC105 plus bevacizumab versus bevacizumab in recurrent glioblastoma: North Central Cancer Treatment Group N1174 (Alliance). Neurooncol Adv 4(1):vdac041. https:\/\/doi.org\/10.1093\/noajnl\/vdac041","journal-title":"Neurooncol Adv"},{"issue":"1","key":"4734_CR16","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1007\/s10585-010-9356-6","volume":"28","author":"M Lakshman","year":"2011","unstructured":"Lakshman M, Huang X, Ananthanarayanan V, Jovanovic B, Liu Y, Craft CS, Romero D, Vary CP, Bergan RC (2011) Endoglin suppresses human prostate cancer metastasis. Clin Exp Metastasis 28(1):39\u201353. https:\/\/doi.org\/10.1007\/s10585-010-9356-6","journal-title":"Clin Exp Metastasis"},{"issue":"9","key":"4734_CR17","doi-asserted-by":"publisher","first-page":"1046","DOI":"10.1038\/onc.2010.488","volume":"30","author":"LA Henry","year":"2011","unstructured":"Henry LA, Johnson DA, Sarri\u00f3 D, Lee S, Quinlan PR, Crook T, Thompson AM, Reis-Filho JS, Isacke CM (2011) Endoglin expression in breast tumor cells suppresses invasion and metastasis and correlates with improved clinical outcome. Oncogene 30(9):1046\u20131058. https:\/\/doi.org\/10.1038\/onc.2010.488","journal-title":"Oncogene"},{"issue":"3","key":"4734_CR18","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1093\/carcin\/bgp217","volume":"31","author":"D Romero","year":"2010","unstructured":"Romero D, Terzic A, Conley BA, Craft CS, Jovanovic B, Bergan RC, Vary CP (2010) Endoglin phosphorylation by ALK2 contributes to the regulation of prostate cancer cell migration. Carcinogenesis 31(3):359\u2013366. https:\/\/doi.org\/10.1093\/carcin\/bgp217","journal-title":"Carcinogenesis"},{"issue":"51","key":"4734_CR19","doi-asserted-by":"publisher","first-page":"7240","DOI":"10.1038\/sj.onc.1210533","volume":"26","author":"C Craft","year":"2007","unstructured":"Craft C, Romero D, Vary C, Bergan R (2007) Endoglin inhibits prostate cancer motility via activation of the ALK2-Smad1 pathway. Oncogene 26(51):7240\u20137250","journal-title":"Oncogene"},{"issue":"6","key":"4734_CR20","doi-asserted-by":"publisher","first-page":"970","DOI":"10.1038\/bjc.2015.302","volume":"113","author":"K O\u2019Leary","year":"2015","unstructured":"O\u2019Leary K, Shia A, Cavicchioli F, Haley V, Comino A, Merlano M, Mauri F, Walter K, Lackner M, Wischnewsky MB, Crook T, Lo Nigro C, Schmid P (2015) Identification of Endoglin as an epigenetically regulated tumour-suppressor gene in lung cancer. Br J Cancer 113(6):970\u2013978. https:\/\/doi.org\/10.1038\/bjc.2015.302","journal-title":"Br J Cancer"},{"key":"4734_CR21","doi-asserted-by":"publisher","first-page":"9305","DOI":"10.2147\/CMAR.S338957","volume":"13","author":"CH Li","year":"2021","unstructured":"Li CH, Ko JL, Hsiao YP, Tsai MH, Lai YC, Hsin IL, Kang YT, Sheu GT, Lin WL, Wu MF (2021) Plasma endoglin is Associated with Favorable Outcome for Pemetrexed-based therapy in Advanced Non-small Cell Lung Cancer. Cancer Manag Res 13:9305\u20139318. https:\/\/doi.org\/10.2147\/CMAR.S338957","journal-title":"Cancer Manag Res"},{"key":"4734_CR22","doi-asserted-by":"publisher","unstructured":"Gonz\u00e1lez Mu\u00f1oz T, Amaral AT, Puerto-Camacho P, Peinado H, de \u00c1lava E (2021) Endoglin in the spotlight to treat cancer. Int J Mol Sci 22(6). https:\/\/doi.org\/10.3390\/ijms22063186","DOI":"10.3390\/ijms22063186"},{"issue":"1\u20133","key":"4734_CR23","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.ejphar.2011.04.057","volume":"663","author":"TY Yang","year":"2011","unstructured":"Yang TY, Chang GC, Chen KC, Hung HW, Hsu KH, Sheu GT, Hsu SL (2011) Sustained activation of ERK and Cdk2\/cyclin-A signaling pathway by pemetrexed leading to S-phase arrest and apoptosis in human non-small cell lung cancer A549 cells. Eur J Pharmacol 663(1\u20133):17\u201326. https:\/\/doi.org\/10.1016\/j.ejphar.2011.04.057","journal-title":"Eur J Pharmacol"},{"key":"4734_CR24","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.dnarep.2016.04.008","volume":"42","author":"A Karimian","year":"2016","unstructured":"Karimian A, Ahmadi Y, Yousefi B (2016) Multiple functions of p21 in cell cycle, apoptosis and transcriptional regulation after DNA damage. DNA Repair (Amst) 42:63\u201371. https:\/\/doi.org\/10.1016\/j.dnarep.2016.04.008","journal-title":"DNA Repair (Amst)"},{"key":"4734_CR25","doi-asserted-by":"publisher","unstructured":"Kreis NN, Louwen F, Yuan J (2019) The multifaceted p21 (Cip1\/Waf1\/CDKN1A) in cell differentiation, Migration and Cancer Therapy. Cancers (Basel) 11(9). https:\/\/doi.org\/10.3390\/cancers11091220","DOI":"10.3390\/cancers11091220"},{"issue":"33","key":"4734_CR26","doi-asserted-by":"publisher","first-page":"3904","DOI":"10.1038\/onc.2013.5","volume":"32","author":"YH Lin","year":"2013","unstructured":"Lin YH, Huang YH, Wu MH, Wu SM, Chi HC, Liao CJ, Chen CY, Tseng YH, Tsai CY, Tsai MM, Lin KH (2013) Thyroid hormone suppresses cell proliferation through endoglin-mediated promotion of p21 stability. Oncogene 32(33):3904\u20133914. https:\/\/doi.org\/10.1038\/onc.2013.5","journal-title":"Oncogene"},{"issue":"1","key":"4734_CR27","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1186\/s13045-021-01053-x","volume":"14","author":"B-G Kim","year":"2021","unstructured":"Kim B-G, Malek E, Choi SH, Ignatz-Hoover JJ, Driscoll JJ (2021) Novel therapies emerging in oncology to target the TGF-\u03b2 pathway. J Hematol Oncol 14(1):55. https:\/\/doi.org\/10.1186\/s13045-021-01053-x","journal-title":"J Hematol Oncol"},{"issue":"1","key":"4734_CR28","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1002\/dvdy.338","volume":"251","author":"JB Pawlak","year":"2022","unstructured":"Pawlak JB, Blobe GC (2022) TGF-\u03b2 superfamily co-receptors in cancer. Dev Dyn 251(1):137\u2013163. https:\/\/doi.org\/10.1002\/dvdy.338","journal-title":"Dev Dyn"},{"issue":"3","key":"4734_CR29","doi-asserted-by":"publisher","first-page":"1459","DOI":"10.21873\/anticanres.14088","volume":"40","author":"AC Vidal","year":"2020","unstructured":"Vidal AC, Duong F, Howard LE, Wiggins E, Freedland SJ, Bhowmick NA, Gong J (2020) Soluble endoglin (sCD105) as a Novel Biomarker for detecting aggressive prostate Cancer. Anticancer Res 40(3):1459\u20131462. https:\/\/doi.org\/10.21873\/anticanres.14088","journal-title":"Anticancer Res"},{"key":"4734_CR30","doi-asserted-by":"publisher","first-page":"1112573","DOI":"10.3389\/fmed.2023.1112573","volume":"10","author":"SK Hakuno","year":"2023","unstructured":"Hakuno SK, Janson SGT, Trietsch MD, de Graaf M, de Jonge-Muller E, Crobach S, Harryvan TJ, Boonstra JJ, Dinjens WNM, Slingerland M, Hawinkels L (2023) Endoglin and squamous cell carcinomas. Front Med (Lausanne) 10:1112573. https:\/\/doi.org\/10.3389\/fmed.2023.1112573","journal-title":"Front Med (Lausanne)"},{"issue":"11","key":"4734_CR31","doi-asserted-by":"publisher","first-page":"2499","DOI":"10.1002\/mc.22697","volume":"56","author":"XF Zhang","year":"2017","unstructured":"Zhang XF, Weng DS, Pan K, Zhou ZQ, Pan QZ, Zhao JJ, Tang Y, Jiang SS, Chen CL, Li YQ, Zhang HX, Chang AE, Wicha MS, Zeng YX, Li Q, Xia JC (2017) Dendritic-cell-based immunotherapy evokes potent anti-tumor immune responses in CD105\u2009+\u2009human renal cancer stem cells. Mol Carcinog 56(11):2499\u20132511. https:\/\/doi.org\/10.1002\/mc.22697","journal-title":"Mol Carcinog"},{"issue":"3","key":"4734_CR32","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1002\/cam4.207","volume":"3","author":"Y Liu","year":"2014","unstructured":"Liu Y, Starr MD, Brady JC, Dellinger A, Pang H, Adams B, Theuer CP, Lee NY, Hurwitz HI, Nixon AB (2014) Modulation of circulating protein biomarkers following TRC105 (anti-endoglin antibody) treatment in patients with advanced cancer. Cancer Med 3(3):580\u2013591. https:\/\/doi.org\/10.1002\/cam4.207","journal-title":"Cancer Med"},{"issue":"3","key":"4734_CR33","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1016\/j.lungcan.2010.10.012","volume":"72","author":"SG Wu","year":"2011","unstructured":"Wu SG, Yang CH, Yu CJ, Lee JH, Hsu YC, Chang YL, Shih JY, Yang PC (2011) Good response to pemetrexed in patients of lung adenocarcinoma with epidermal growth factor receptor (EGFR) mutations. Lung Cancer 72(3):333\u2013339. https:\/\/doi.org\/10.1016\/j.lungcan.2010.10.012","journal-title":"Lung Cancer"}],"container-title":["Cancer Chemotherapy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-024-04734-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00280-024-04734-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-024-04734-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,10]],"date-time":"2025-01-10T09:02:21Z","timestamp":1736499741000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00280-024-04734-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,10]]},"references-count":33,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["4734"],"URL":"https:\/\/doi.org\/10.1007\/s00280-024-04734-9","relation":{},"ISSN":["0344-5704","1432-0843"],"issn-type":[{"value":"0344-5704","type":"print"},{"value":"1432-0843","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,10]]},"assertion":[{"value":"9 July 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 December 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 January 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"20"}}